2-(4-fluorophenyl)thiosemicarbazide | 89521-93-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-fluorophenyl)thiosemicarbazide
• 英文别名: 1-(4-Fluorophenyl)hydrazine-1-carbothioamide；1-amino-1-(4-fluorophenyl)thiourea
• CAS: 89521-93-7
• 化学式: C₇H₈FN₃S
• 分子量: 185.225
• InChiKey: LLMWCXJJIZYRFG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  87.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-fluorophenyl)thiosemicarbazide 以 四氢呋喃 、 甲醇 为溶剂， 反应 5.0h， 生成 1-(4-fluorophenyl)-3-trifluoromethyl-5-methylthio-1,2,4-triazole
  参考文献：
  名称：

  Pilgram, Kurt H.; Skiles, Richard D., Journal of Heterocyclic Chemistry, 1983, vol. 20, p. 1533 - 1537

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(4-fluorophenyl)hydrazine-1-carbonitrile 在 硫化氢 、 三乙胺 作用下， 以 乙醇 为溶剂， 以82%的产率得到2-(4-fluorophenyl)thiosemicarbazide
  参考文献：
  名称：

  Pilgram, Kurt H.; Skiles, Richard D., Journal of Heterocyclic Chemistry, 1983, vol. 20, p. 1533 - 1537

  摘要：

  DOI：

文献信息

• [EN] PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES<br/>[FR] COMPOSÉS PYRAZOLO[3,4-B]PYRIDINE UTILISÉS EN TANT QU'INHIBITEURS DE KINASES TAM ET MET
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2020047184A1

  公开（公告）日：2020-03-05

  Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R9, X1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.

  本文提供了Formula (I)的化合物及其立体异构体、互变异构体和药学上可接受的盐，其中R1、R2、R9、X1和G如本文所定义，它们是一种或多种TAM激酶和/或c-Met激酶的抑制剂，并且在治疗和预防可以用TAM激酶抑制剂和/或c-Met激酶抑制剂治疗的疾病中非常有用。
• [EN] INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE<br/>[FR] COMPOSÉS D'INDOLE-OXADIAZOLE ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：GOVERNING COUNCIL UNIV TORONTO

  公开号：WO2020051707A1

  公开（公告）日：2020-03-19

  The present application pertains to methods of using indole-oxadiazole compounds of Formula I to modulate cannabinoid receptor activity: I In particular diseases, disorders or conditions that benefit from modulating cannabinoid receptor activity, such as non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), schizophrenia, bipolar disorder, psychosis, metabolic syndrome, type-2 diabetes, dyslipidaemia, obesity, eating disorders, cardiovascular diseases and disorders, and other conditions as described herein, may be treated. Also included in the present application are certain novel compounds of Formula Ia and pharmaceutical compositions comprising these compounds.

  本申请涉及使用式I的吲哚-噁二唑化合物调节大麻素受体活性的方法：I 特别是在需要调节大麻素受体活性的疾病、障碍或病况，例如非酒精性脂肪性肝炎（NASH）、非酒精性脂肪肝病（NAFLD）、精神分裂症、躁郁症、精神病、代谢综合征、2型糖尿病、血脂异常、肥胖症、进食障碍、心血管疾病和其他如本文所述的病症，可以得到治疗。本申请还包括式Ia的某些新化合物和包含这些化合物的制药组合物。
• PILGRAM, K. H.;SKILES, R. D., J. HETEROCYCL. CHEM., 1983, 20, N 6, 1533-1537
  作者：PILGRAM, K. H.、SKILES, R. D.

  DOI：——

  日期：——
• PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES
  申请人：Array BioPharma Inc.

  公开号：EP3843850A1

  公开（公告）日：2021-07-07
• PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES
  申请人：Array BioPharma Inc.

  公开号：US20200079770A1

  公开（公告）日：2020-03-12

  Provided herein are compounds of the Formula I: and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 9 , X 1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.